Altimmune Inc [NASDAQ: ALT] loss -1.72% or -0.15 points to close at $8.59 with a heavy trading volume of 2501949 shares.
The daily chart for ALT points out that the company has recorded 29.95% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 3.01M shares, ALT reached to a volume of 2501949 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Altimmune Inc [ALT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALT shares is $22.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALT stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Altimmune Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 12, 2024. The new note on the price target was released on April 29, 2024, representing the official price target for Altimmune Inc stock. Previously, the target price had yet another raise to $13, while Goldman analysts kept a Neutral rating on ALT stock. On March 22, 2023, analysts decreased their price target for ALT shares from 20 to 6.
The Average True Range (ATR) for Altimmune Inc is set at 0.81, with the Price to Sales ratio for ALT stock in the period of the last 12 months amounting to 12219.23. The Price to Book ratio for the last quarter was 4.58, with the Price to Cash per share for the same quarter was set at 1.96.
Trading performance analysis for ALT stock
Altimmune Inc [ALT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.02. With this latest performance, ALT shares dropped by -9.48% in over the last four-week period, additionally plugging by 29.95% over the last 6 months – not to mention a rise of 44.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALT stock in for the last two-week period is set at 51.63, with the RSI for the last a single of trading hit 47.90, and the three-weeks RSI is set at 53.24 for Altimmune Inc [ALT]. The present Moving Average for the last 50 days of trading for this stock 7.60, while it was recorded at 9.02 for the last single week of trading, and 7.51 for the last 200 days.
Altimmune Inc [ALT]: A deeper dive into fundamental analysis
Altimmune Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.87 and a Current Ratio set at 16.87.
An analysis of Institutional ownership at Altimmune Inc [ALT]
There are presently around $56.74%, or 57.19%% of ALT stock, in the hands of institutional investors. The top three institutional holders of ALT stocks are: BLACKROCK INC. with ownership of 5.32 million shares, which is approximately 7.5155%. VANGUARD GROUP INC, holding 4.91 million shares of the stock with an approximate value of $$32.63 million in ALT stocks shares; and VANGUARD GROUP INC, currently with $$26.0 million in ALT stock with ownership which is approximately 5.5215%.
